Related Experiment Video
Updated: Apr 18, 2026
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Precision cardiovascular risk prediction in type 1 diabetes: An IMI2 SOPHIA analysis
Sofia Pazmino1, Stefanie Schmid2,3, Jordi Blanch4,5
1Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium. sofia.pazmino.lucio@gmail.com.
Insights
Cardiovascular disease (CVD) risk in type 1 diabetes (T1D) can be assessed using European risk profiles. Improved glycemic control, indicated by lower glycated hemoglobin, is linked to reduced CVD risk in T1D patients.
Area of Science:
- Endocrinology
- Cardiology
- Diabetes Research
Background:
- Cardiovascular disease (CVD) is a leading cause of death in type 1 diabetes (T1D).
- Multiple risk factors contribute to higher CVD prevalence in T1D compared to the general population.
- Accurate CVD risk assessment is crucial for tailored prevention strategies in T1D.
Purpose of the Study:
- To evaluate the applicability of five CVD phenotypic risk profiles, identified in the general European population, to individuals with T1D.
- To investigate the relationship between glycemic control and CVD risk profiles in a large T1D cohort.
Main Methods:
- Analysis of data from 44,212 individuals with T1D.
- Application of five previously identified CVD phenotypic risk profiles.
- Assessment of the association between glycated hemoglobin levels and CVD risk clusters.
Main Results:
- The five CVD phenotypic risk profiles are applicable to people with T1D.
- Improved glycemic control, indicated by lower glycated hemoglobin, correlated with membership in a lower-risk cluster.
- This suggests a link between better glycemic management and reduced CVD risk in the T1D population.
Conclusions:
- Phenotypic CVD risk profiles identified in the general population can be applied to individuals with T1D.
- Glycemic control is an integral component of CVD risk reduction in T1D.
- These findings support personalized CVD prevention approaches for T1D patients based on risk profiling and glycemic status.
Abstract:
Cardiovascular disease (CVD) is a major long-term complication and the leading cause of morbidity and mortality among individuals with type 1 diabetes (T1D), with a substantially higher prevalence compared to the general population and driven by multiple interrelated risk factors-underscoring the urgent need for accurate risk assessment. To support more tailored approaches to CVD prevention, recently, five discordant phenotypic risk profiles for CVD were identified in the general population in Europe with diverse relationship between body mass index and cardiometabolic biomarkers. Here, we show their applicability in 44,212 people with T1D. Improved glycemic control was linked to a decrease in CVD risk as people with T1D with lower glycated hemoglobin belonged to the baseline concordant cluster. This supports the contention that glycemic control in people with T1D is an integral part of lowering CVD risk.
Related Concept Videos
01:26Type I Diabetes II: Pathophysiology
01:12Type I Diabetes I: Introduction
01:24Type II Diabetes II: Pathophysiology
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Type II Diabetes I: Introduction
01:22Diabetes Mellitus: Type 2 and Gestational